About: Autoinflammatory and autoimmune conditions at the crossroad of COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Autoinflammatory and autoimmune conditions at the crossroad of COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Autoinflammatory and autoimmune conditions at the crossroad of COVID-19
Creator	Ansari, Aftab Selmi, Carlo Gershwin, M De Santis, Maria Ridgway, William Acosta-Ampudia, Yeny Anaya, Juan-Manuel Costanzo, Antonio Monsalve, Diana Novelli, Lucia Ramírez-Santana, Carolina Rodríguez, Yhojan Rojas, Manuel
source	Elsevier; Medline; PMC
abstract	Coronavirus disease 2019 (COVID-19) has been categorized as evolving in overlapping phases. First, there is a viral phase that may well be asymptomatic or mild in the majority, perhaps 80% of patients. The pathophysiological mechanisms resulting in minimal disease in this initial phase are not well known. In the remaining 20% of cases, the disease may become severe and/or critical. In most patients of this latter group, there is a phase characterized by the hyperresponsiveness of the immune system. A third phase corresponds to a state of hypercoagulability. Finally, in the fourth stage organ injury and failure occur. Appearance of autoinflammatory/autoimmune phenomena in patients with COVID-19 calls attention for the development of new strategies for the management of life-threatening conditions in critically ill patients. Antiphospholipid syndrome, autoimmune cytopenia, Guillain-Barré syndrome and Kawasaki disease have each been reported in patients with COVID-19. Here we present a scoping review of the relevant immunological findings in COVID-19 as well as the current reports about autoimmune/autoinflammatory conditions associated with the disease. These observations have crucial therapeutic implications since immunomodulatory drugs are at present the most likely best candidates for COVID-19 therapy. Clinicians should be aware of these conditions in patients with COVID-19, and these observations should be considered in the current development of vaccines.
has issue date	2020-06-16(xsd:dateTime)
bibo:doi	10.1016/j.jaut.2020.102506
bibo:pmid	32563547
has license	no-cc
sha1sum (hex)	2e71f76f3f5a949a25e05598856096dc685d350e
schema:url	https://doi.org/10.1016/j.jaut.2020.102506
resource representing a document's title	Autoinflammatory and autoimmune conditions at the crossroad of COVID-19
has PubMed Central identifier	PMC7296326
has PubMed identifier	32563547
schema:publication	J Autoimmun
resource representing a document's body	covid:2e71f76f3f5a949a25e05598856096dc685d350e#body_text
is schema:about of	named entity 'crossroad' named entity 'Autoinflammatory' named entity 'Autoinflammatory' named entity 'fever' named entity 'macrophage inflammatory proteins' named entity 'spike protein' named entity 'SARS-CoV-2' named entity 'TNFα' named entity 'hypogeusia' named entity 'CD8' named entity 'lymphopenia' named entity 'type I diabetes' named entity 'symptom' named entity 'systemic juvenile idiopathic arthritis' named entity 'G-CSF' named entity 'organ damage' named entity 'AOSD' named entity 'amino acids' named entity 'macrophages' named entity 'GBS' named entity 'macrophages' named entity 'bradykinin' named entity 'SARS-CoV-2' named entity 'coronary arteries' named entity 'AOSD' named entity 'cytolytic' named entity 'COVID' named entity 'microorganism' named entity 'COVID-19' named entity 'produce antibodies' named entity 'rash' named entity 'acute phase' named entity 'IL-6' named entity 'IgG antibodies' named entity 'Th17 cells' named entity 'COVID-19' named entity 'SARS-CoV-2 virus' named entity 'autoimmune conditions' named entity 'critically ill' named entity 'Th1 polarization' named entity 'hematological' named entity 'danger signals' named entity 'autoimmune conditions' named entity 'GBS' named entity 'virus' named entity 'neurological symptoms' named entity 'pericardial effusion' named entity 'autoinflammatory' named entity 'CD4+ T cells' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'IVIG' named entity 'COVID' named entity 'biomarker' named entity 'CD4+ T cells' named entity 'COVID-19' named entity 'deep vein thrombosis' named entity 'Zika' named entity 'transporter protein' named entity 'infection' named entity 'clinical trials' named entity 'vasculitis' named entity 'cytomegalovirus' named entity 'brainstem' named entity 'IL-8' named entity 'symptom' named entity 'Cytomegalovirus' named entity 'spike protein' named entity 'antibodies'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software